Considering that in recent years, increasingly more differences have been found among PD subtypes, which have been attributed to the heterogeneity of various motor subtypes, such as LRRK2 and GBA mutations, CSF concentrations of beta-amyloid 1–42, tau, and alpha-synuclein (39–41), we will incorporate these biomarkers into our cohort study for better evaluation and discrimination between motor subtypes in our further studies. This evidence concerns the gene MAPT and Parkinson disease.